Key facts
- Shift Bioscience’s last known valuation is $30.5M.
- It has raised $17.5M; the latest was Seed Round ($10.9M) in Jun 2024.
- Notable investors include F-Prime Capital, Boost VC, BGF (Financial Services), Meltwind Advisory, Jonathan Milner — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Shift Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Shift Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Shift Bioscience
Operator of a biotechnology company intended to develop simulation-guided cell rejuvenation therapies to address the diseases of aging. The company utilizes simulation-guided techniques to discover gene-based interventions that rejuvenate cells without altering stem cell identity by identifying interventions that reverse epigenetic age markers, including single-gene therapies, enabling healthcare professionals to promote healthy aging.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2017
- Employees
- 25
- Website
- shiftbioscience.com/
- Ownership
- Privately Held (backing)
Shift Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Shift Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Shift Bioscience in its N-PORT filings yet. We sweep new filings monthly.